How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,570 results for

NIH Stroke Scale

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke

. Patients must have a score on the NIH Stroke Scale 8-24, and mRS ≤ 1 Women of childbearing age should have a negative pregnancy test performed prior to inclusion Obtaining informed consent signed Exclusion Criteria: Comatose patients. brain tumour, cerebral oedema with compression of ventricles, cerebellar infarction or brainstem, or intraventricular, intracerebral or subarachnoid haemorrhage. alcohol use Active infectious disease, including HIV, hepatitis B, Hepatitis . patients with dementia. Specify (...) patients aged 40-80 years with symptoms of acute cerebral infarction of less than 24h from stroke onset. Patients with infarct size 3*3 Patients with a measurable focal neurological that must persist to the time of treatment without clinically meaningful improvement. Patients must have computerized tomography (CT) and / or magnetic resonance imaging (MRI) compatible with the clinical diagnosis of acute ischemic stroke in the territory of the middle cerebral artery before being included in the study

2017 Clinical Trials

142. Comparison of Fatigue and Recovery After Stroke Depending on the Usual Management With or Without Physical Training

hospitalisation (NIH score ≥ 6) Recurrence of the cerebrovascular event or onset of an acute cardio-vascular event between the screening and definitive inclusion Pre-stroke Rankin score ≥ 3 Pregnant patient Patient under guardianship Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov (...) contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Age > 18 years National health insurance cover 1st minor ischaemic stroke (initial NIH score ≤ 4) Satisfactory neurological recovery at discharge from hospital (modified Rankin score ≤2) Patient living close

2017 Clinical Trials

143. Enhanced Reality for Hemiparetic Arm in the Stroke Patients

information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Arm motor Fugl-Mayer scale; wrist/hand subscales ≥ 2-20 9-hole pegboard ; ≥ 25% of contra-lateral hand Exclusion Criteria: Alexander apraxia scale ≤2 NIH stroke scale question Ia-c ≥1 Nottingham sensory scale; <75% of contra-lateral hand Ashworth scale ≥3 NIH stroke scale question IX ≥2 Beck (...) termination of treatment ] 9-hole pegboard Change of Stroke impact scale [ Time Frame: 1 day before the initiation of intervention, 10 day after the initiation of intervention, and 30 days after termination of treatment ] Stroke impact scale, hand function Change of Grasp force in Newtons [ Time Frame: 1 day before the initiation of intervention, 10 day after the initiation of intervention, and 30 days after termination of treatment ] Grasp force in Newtons Change of Active range of motion of wrist joint

2017 Clinical Trials

144. Evaluation Of HUK in Acute Stroke Patients: MRS and CTP

, controlled trial in which ischemic stroke patients will be randomized to treatment with either HUK or regular treatment within 72 hours of symptom onset. The study includes two MRS and two CTP scannings (before and after 2 week treatment) for all randomized subjects. The endpoints will include improvement of the NIH Stroke Scale (NIHSS) score from baseline, modified Rankin scale (mRS) score and Barthel index at 14 days. EvHUKMRS will test the following hypotheses: HUK enhanced N-acetylaspartate (NAA (...) Description Go to Brief Summary: Background: Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality worldwide. Human urinary kallidinogenase (HUK), a glycoprotein extracted from male urine currently used in China for enhancing cerebral perfusion5, plays a neuroprotective role including promoting angiogenesis, enhancing cerebral perfusion and suppressing the inflammatory response in animals and in patients with respect to regulating the kallikrein-kinin system. In previous clinical

2017 Clinical Trials

145. Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke

by Neuralstem Inc. ( Suzhou Neuralstem Biopharmaceuticals ): chronic stroke neural stem cell transplant paralysis Additional relevant MeSH terms: Layout table for MeSH terms Stroke Ischemia Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes (...) cells to 8×107 cells, as tolerated. Outcome Measures Go to Primary Outcome Measures : Adverse Events [ Time Frame: 24 months ] Secondary Outcome Measures : Clinical improvement using NIH Stroke Scale [ Time Frame: 12 months ] Clinical improvement using Modified Rankin Scale [ Time Frame: 12 months ] Clinical improvement using Fugl-Meyer Motor Score [ Time Frame: 12 months ] Clinical Improvement using Mini-mental State Examination [ Time Frame: 12 months ] Other Outcome Measures: MRI analysis

2017 Clinical Trials

146. Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Stroke Ischemia Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes Brain Infarction Brain Ischemia Kallikreins Coagulants Fertility Agents, Male Fertility Agents Reproductive (...) baseline to Day 90 of NIH Stroke Scale. [ Time Frame: 90 Days ] Assessed by a reduction in points from baseline. Changes from baseline to Day 90 of Barthel Index. [ Time Frame: 90 Days ] Assessed by an increase in points from baseline. Changes from baseline to Day 90 of Modified Rankin Scale. [ Time Frame: 90 Days ] Assessed by a reduction in points from baseline. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal

2017 Clinical Trials

147. Early arrival at the emergency department is associated with better collaterals, smaller established infarcts and better clinical outcomes with endovascular stroke therapy: SWIFT study. Full Text available with Trip Pro

Early arrival at the emergency department is associated with better collaterals, smaller established infarcts and better clinical outcomes with endovascular stroke therapy: SWIFT study. Increasing time from symptom onset to emergency department arrival may incur greater ischemic injury and decreased likelihood of good outcomes after acute stroke therapy. The impact of time may be assessed bythe extent of acute CT changes, status of collateral vessels, and clinical outcomes.The SOLITAIRE FR (...) With the Intention For Thrombectomy (SWIFT) trial comparing two neurothrombectomy treatments was analyzed by time, Alberta Stroke Program Early CT Scores (ASPECTS), angiographic collaterals, and 90-day modified Rankin Scale outcomes. We determined the interaction of time with ASPECTS, collateral grade, reperfusion, and clinical outcomes, with established determinants of angiographic and clinical outcomes as covariates.137 patients (52% female) of mean age 67±12 years and median pretreatment NIH Stroke Scale

2017 Journal of neurointerventional surgery Controlled trial quality: uncertain

148. Electric Field Navigated 1hz Rtms for Post-stroke Motor Recovery Trial

or Cleared by U.S. FDA: Yes Product Manufactured in and Exported from the U.S.: No Keywords provided by Nexstim Ltd: Stroke rTMS Motor rehabilitation Additional relevant MeSH terms: Layout table for MeSH terms Stroke Ischemia Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes (...) (ARAT) [ Time Frame: Baseline to 6 months after end of treatment ] NIH Stroke Scale (NIHSS) [ Time Frame: Baseline to 6 months after end of treatment ] Quality of life assessment: EQ-5D [ Time Frame: Baseline to 6 months after end of treatment ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about

2017 Clinical Trials

149. Lycra Orthosis as Therapy for the Upper Limb After Stroke

be recorded to assess feasibility of a full-scale trial. Condition or disease Intervention/treatment Phase Stroke Cerebrovascular Accident Device: Dynamic Lycra Orthosis Other: Usual Rehabilitation Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 43 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Feasibility Randomised Controlled Trial Masking: Single (Outcomes (...) and extinction [ Time Frame: 8 weeks ] NIH Stroke Scale item 11, test of inattention and extinction: Total possible score = 4, maximum of 2 each for extinction and inattention: 0 = No abnormality, 1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities, 2 = Profound hemi-inattention or hemi-inattention to more than one modality. Unilateral inattention and extinction [ Time Frame: 16 weeks ] NIH Stroke Scale item 11

2017 Clinical Trials

150. Effect of External Counter Pulsation on Ischemic Stroke

relevant MeSH terms: Layout table for MeSH terms Stroke Ischemia Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes Brain Infarction Brain Ischemia (...) , you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Clinical diagnosis of ischemic stroke Exclusion cerebral hemorrhage after CT scan NIH Stroke Scale (NIHSS)≥4 Modified Rankin Scale (mRS) 0-1 Signed informed consent Exclusion Criteria

2017 Clinical Trials

151. Cohort of Ischemic STROKE Patients

table for MeSH terms Stroke Ischemia Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes Brain Infarction Brain Ischemia (...) : October 2026 Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Degree of disability (mRS Score) [ Time Frame: 5 years ] Degree of disability: modified Rankin Score Secondary Outcome Measures : infarct size [ Time Frame: day 6 ] cerebral infarct size on MRI Hemorrhagic transformation [ Time Frame: 24 hours ] Hemorrhagic transformation (ECASS scale) on imaging (CT or MRI) Neurological deficit [ Time Frame: up to 5 years ] Neurological deficit NIH stroke Scale Quality of life

2017 Clinical Trials

152. Use of Vibration to Improve Visual/Spatial Neglect in Patients Affected by Stroke

or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: 18 years old or older demonstrated visual/spatial neglect, as demonstrated by NIH Stroke Scale (NIHSS) and deficits in assessing tactile extinction and visuospatial neglect done on admission (...) Use of Vibration to Improve Visual/Spatial Neglect in Patients Affected by Stroke Use of Vibration to Improve Visual/Spatial Neglect in Patients Affected by Stroke - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2017 Clinical Trials

153. Wearable Device for Motivating Hand Use After Stroke

2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases (...) by (Responsible Party): David Reinkensmeyer, University of California, Irvine Study Details Study Description Go to Brief Summary: The goal of this study is to determine the effectiveness of interactive feedback from a wearable device that senses hand function, the Manumeter, in improving upper extremity function in a pilot, randomized controlled trial with chronic stroke patients Condition or disease Intervention/treatment Phase Cerebral Stroke Device: Manumeter Not Applicable Detailed Description

2017 Clinical Trials

154. Quelling of Excitotoxicity in Acute Stroke With Ketamine

injection Injection Other Name: Versed Outcome Measures Go to Primary Outcome Measures : Change in weighted modified Rankin scale score between day 1 and 90 will be assessed. [ Time Frame: On day 1 and at 90 days ] An improvement of 2 in mRS score will be considered favorable outcome. Secondary Outcome Measures : Barthel's index [ Time Frame: On day 1, and at 90 days ] An improvement of 10 or more points in Barthel's index will be considered a favorable outcome. NIH stroke scale score [ Time Frame (...) ] Deterioration in neurologic status [ Time Frame: Up to day 4 or discharge whichever is earlier ] Increase of 4 or more points in the NIH stroke scale Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below

2017 Clinical Trials

155. Pilot Study of Acute Stroke Using the Brainpulseâ„¢

Stroke, Transient Ischemic Attack or No Stroke. The data collected from the BrainPulse will be compared across the four different study groups in an attempt to distinguish stroke from other non-stroke conditions that present with similar symptoms. Further assessments will also be made to evaluate if the BrainPulse can distinguish between hemorrhagic and ischemic stroke. Condition or disease Intervention/treatment Stroke, Acute Device: BrainPulse Device Detailed Description: The study is a prospective (...) in the Stroke patient care workflow. Patients will be consecutively recruited and once patients have consented and met eligibility, they will be assigned to one of the four study Groups based on their confirmed clinical diagnosis. Each subject will complete one BrainPulse recording before neuro-intervention and within one hour of IV pharmacologic intervention. All subjects will also complete comprehensive neurological, cognitive and NIH Stroke Scale (NIHSS) assessments. Additionally, Ischemic Stroke

2017 Clinical Trials

156. Endovascular therapy for ischemic stroke: Save a minute-save a week. (Abstract)

Endovascular therapy for ischemic stroke: Save a minute-save a week. To quantify the patient lifetime benefits gained from reduced delays in endovascular therapy for acute ischemic stroke.We used observational prospective data of consecutive stroke patients treated with IV thrombolysis in Helsinki (1998-2014; n = 2,474) to describe distributions of age, sex, stroke severity, onset-to-treatment times, and 3-month modified Rankin Scale (mRS) in routine clinical practice. We used treatment effects (...) by time of endovascular therapy in large vessel occlusion over and above thrombolysis as reported by the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) study to model the shift in 3-month mRS distributions with reducing treatment delays. From the 3-month outcomes we derived patient-expected lifetimes and cumulative long-term disability with incremental treatment delay reductions.Each minute saved in onset-to-treatment time

2017 Neurology

157. Integrity of normal-appearing white matter and functional outcomes after acute ischemic stroke. Full Text available with Trip Pro

Integrity of normal-appearing white matter and functional outcomes after acute ischemic stroke. To characterize the effect of white matter microstructural integrity on cerebral tissue and long-term functional outcomes after acute ischemic stroke (AIS).Consecutive AIS patients with brain MRI acquired within 48 hours of symptom onset and 90-day modified Rankin Scale (mRS) score were included. Acute infarct volume on diffusion-weighted imaging (DWIv) and white matter hyperintensity volume (WMHv (...) patients with DWIv and mRS score, mean age was 64.4 ± 15.9 years, and 183 participants (60%) were male. Median NIH Stroke Scale (NIHSS) score was 3 (interquartile range [IQR] 1-8), and median normalized WMHv was 6.19 cm3 (IQR 3.0-12.6 cm3). Admission stroke severity (β = 0.16, p < 0.0001) and small vessel stroke subtype (β = -1.53, p < 0.0001), but not diffusivity metrics, were independently associated with DWIv. However, median FA in contralesional NAWM was independently associated with mRS score (β

2017 Neurology

158. Tenecteplase in ischemic stroke offers improved recanalization: Analysis of 2 trials. (Abstract)

and at 24 hours post thrombolysis using the modified thrombolysis in cerebral infarction (TICI) scale. Twenty-four-hour poststroke NIH Stroke Scale (NIHSS) and 90-day modified Rankin Scale (mRS) scores were also compared between treatment groups using linear regression to generate odds ratios (ORs).From 146 pooled patients, 69 had a TICI 0/1 occlusion overall at baseline. Tenecteplase-treated patients with a complete vessel occlusion had greater complete recanalization rates at 24 hours (71 (...) Tenecteplase in ischemic stroke offers improved recanalization: Analysis of 2 trials. To test whether patients with complete vessel occlusion show greater recanalization at 24 hours and have improved clinical outcomes at 24 hours and 90 days when treated with tenecteplase compared to alteplase.Pooled clinical and imaging data from 2 phase 2 randomized trials comparing tenecteplase with alteplase allowed CT angiography (CTA) scans to be assessed centrally for occlusion status at baseline

2017 Neurology Controlled trial quality: uncertain

159. An Analysis of EMS and ED Detection of Stroke. (Abstract)

alerts, and 131 were ED stroke alerts (70 called by physicians, 61 by nurses). The mean NIH Stroke Scale was higher in the EMS group (8.1 ± 7.6 vs. 3.0 ± 5.0, p < 0.0001). The positive predictive value of EMS stroke alerts was 0.60 (78/129), alerts by ED nurses was 0.25 (15/61), and alerts by ED physicians was 0.31 (22/70). The PPV for EMS was better than for nurses or physicians (both p < 0.001), and more patients in the EMS group had final diagnoses of stroke (62/129 vs. 24/131, p < 0.001 (...) ). The positive likelihood ratio was 1.53 for EMS personnel, 0.45 for physicians, and 0.77 for nurses. The mean time to order the CT (8.5 ± 7.1 min vs. 23.1 ± 18.2 min, p < 0.0001) and the mean ED length of stay (248 ± 116 min vs. 283 ± 128 min, p = 0.022) were shorter for the EMS stroke alert group. More EMS stroke alert patients received tPA (16/129 vs. 6/131, p = 0.027).EMS stroke alerts have better diagnostic test performance than stroke alerts by ED staff, likely due to higher NIH Stroke Scale scores

2017 Prehospital emergency care

160. CT Perfusion to Predict Response to Recanalization in Ischemic Stroke. Full Text available with Trip Pro

on their baseline CT perfusion. Reperfusion was defined as >50% reduction in critical hypoperfusion between the baseline CT perfusion and the 36-hour follow-up magnetic resonance imaging.Of the 201 patients enrolled, 190 patients with an adequate baseline CT perfusion study who underwent angiography were included (mean age = 66 years, median NIH Stroke Scale [NIHSS] = 16, median time from symptom onset to endovascular therapy = 5.2 hours). Rate of reperfusion was 89%. In patients with target mismatch (n = 131 (...) CT Perfusion to Predict Response to Recanalization in Ischemic Stroke. To assess the utility of computed tomographic (CT) perfusion for selection of patients for endovascular therapy up to 18 hours after symptom onset.We conducted a multicenter cohort study of consecutive acute stroke patients scheduled to undergo endovascular therapy within 90 minutes after a baseline CT perfusion. Patients were classified as "target mismatch" if they had a small ischemic core and a large penumbra

2017 Annals of Neurology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>